8-K: Chemed Reports Q2 Earnings Decline, Cuts Full-Year Outlook Amid Rising Medicare Cap Limitations and Executive Departure

Chemed Corporation announced a significant decline in second-quarter earnings and a downward revision to its full-year 2025 guidance, primarily due to increased Medicare Cap billing limitations at its VITAS segment, alongside the resignation of VITAS's CEO.

Summary

• Consolidated revenue increased 3.8% to $618.8 million for the second quarter ended June 30, 2025, compared to the prior-year period.
• GAAP Diluted Earnings-per-Share (EPS) decreased 23.2% to $3.57, while Adjusted Diluted EPS decreased 21.9% to $4.27.
• VITAS segment net patient revenue increased 5.8% to $396.2 million, with Average Daily Census (ADC) up 6.1% to 22,318 and admissions up 1.2% (4.9% excluding one-time prior-year acquisitions).
• VITAS's Net Income, excluding certain discrete items, decreased 23.5% to $38.2 million, and Adjusted EBITDA margin, excluding Medicare Cap, declined 163-basis points to 16.2%.
• VITAS accrued $16.4 million in Medicare Cap billing limitation in Q2 2025, a significant increase from $1.4 million in Q2 2024, including a $9.5 million catch-up for prior periods.
• Roto-Rooter segment revenue increased 0.6% to $222.6 million, but Net Income, excluding certain discrete items, decreased 20.4% to $33.7 million.
• Roto-Rooter's Adjusted EBITDA declined 18.7% to $48.6 million, with its Adjusted EBITDA margin decreasing 517-basis points to 21.8%.
• Chemed revised its full-year 2025 Adjusted Diluted EPS guidance downward to a range of $22.00 to $22.30, from the previously issued range of $24.95 to $25.45.
• Nicholas M. Westfall resigned as Chairman and Chief Executive Officer of VITAS, effective July 29, 2025, and will assist with the transition until December 1, 2025.
• Joel L. Wherley, VITAS President and Chief Operating Officer, will succeed Mr. Westfall as Chief Executive Officer of VITAS.
• As of June 30, 2025, Chemed had $249.9 million in cash and cash equivalents and no current or long-term debt.
• The company repurchased 75,000 shares of Chemed stock for $42.9 million during the quarter, at an average cost of $572.61 per share.

Sentiment

Score: 3

Explanation: The significant downward revision of full-year earnings guidance, coupled with a substantial increase in Medicare Cap billing limitations for the VITAS segment and declining profitability in both segments, indicates a negative outlook. The executive departure, while framed positively, adds an element of uncertainty during a challenging period.

Positives

• Consolidated revenue increased 3.8% to $618.8 million in Q2 2025.
• VITAS segment net patient revenue increased 5.8% to $396.2 million, driven by a 6.1% increase in Average Daily Census (ADC) and a 4.2% Medicare reimbursement rate increase.
• VITAS admissions increased 4.9% in Q2 2025 when excluding one-time admissions from the April 2024 Covenant Health acquisition.
• Chemed maintains a strong balance sheet with $249.9 million in cash and cash equivalents and no current or long-term debt as of June 30, 2025.
• The company has significant undrawn borrowing capacity of approximately $404.5 million under its Credit Agreement.
• Management does not expect a significant level of Medicare Cap billing limitation in the Florida combined program for the 2026 Cap Year, assuming the 2025 rate differential does not recur.
• Recent successful Florida CON VITAS applications and other expansion activities are expected to further mitigate cap risk for 2026 and beyond.

Negatives

• Consolidated GAAP Diluted EPS decreased 23.2% to $3.57 in Q2 2025.
• Consolidated Adjusted Diluted EPS decreased 21.9% to $4.27 in Q2 2025.
• VITAS Net Income, excluding certain discrete items, decreased 23.5% to $38.2 million.
• VITAS Adjusted EBITDA margin, excluding Medicare Cap, declined 163-basis points to 16.2%.
• VITAS accrued a significantly higher Medicare Cap billing limitation of $16.4 million in Q2 2025, compared to $1.4 million in Q2 2024, reflecting weaker than anticipated admissions in Florida.
• Roto-Rooter Net Income, excluding certain discrete items, decreased 20.4% to $33.7 million.
• Roto-Rooter Adjusted EBITDA declined 18.7% to $48.6 million, and its Adjusted EBITDA margin decreased 517-basis points to 21.8%.
• Roto-Rooter's residential drain cleaning, plumbing, and excavation revenues all declined in Q2 2025.
• Full-year 2025 Adjusted Diluted EPS guidance was significantly revised downward to $22.00-$22.30 from $24.95-$25.45, which is also lower than the 2024 reported adjusted EPS of $23.13.

Risks

• Medicare Cap billing limitations pose a significant financial risk, with an estimated $28.2 million in limitations for calendar 2025, including $19 million related to the Florida combined program.
• Acuity mix shift negatively impacted VITAS revenue growth by 71-basis points in Q2 2025.
• The combination of Medicare Cap and other contra revenue changes negatively impacted VITAS revenue growth by 379-basis points.
• Future Medicare reimbursement rates, particularly in Florida, could impact VITAS's financial performance, with detailed rate information for 2026 becoming available in Q3.
• The departure of a key executive, Nicholas M. Westfall, as Chairman and CEO of VITAS, introduces a leadership transition period until December 1, 2025.

Future Outlook

Chemed has revised its full-year 2025 Adjusted Diluted EPS guidance downward to a range of $22.00 to $22.30, a significant reduction from the previously issued range of $24.95 to $25.45. For the VITAS segment, full-year 2025 revenue (prior to Medicare Cap) is estimated to increase 7.5% to 8.5%, with an adjusted EBITDA margin (prior to Medicare Cap) of 18.2% to 18.7%. The company estimates $28.2 million in Medicare Cap billing limitations for calendar 2025. For Roto-Rooter, a revenue increase of 1.25% to 1.75% is forecasted for 2025, with an adjusted EBITDA margin expected to be 23.5% to 24.5%. Management anticipates no significant Medicare Cap billing limitation in the Florida combined program for the 2026 Cap Year, assuming the rate differential does not recur, and plans to update assumptions for 2026 Medicare Cap in the third quarter earnings release.

Management Comments

• Kevin J. McNamara, Chemed's Chief Executive Officer, stated, "Nick has evolved, transformed and cultivated the organization to be well positioned for the future and has elevated VITAS leadership in the industry over the last thirteen years. We thank him for his service and wish him well in his next pursuits."
• Mr. McNamara also commented on Joel L. Wherley's succession, saying, "We look forward to Joels leadership of VITAS. He has spent his entire career in the healthcare industry, with over 15 years in hospice. His deep knowledge of our industry and organization leave him perfectly suited to lead VITAS continued success."

Industry Context

Chemed Corporation operates in two distinct service industries: end-of-life care through its VITAS Healthcare subsidiary and commercial/residential plumbing and drain cleaning services via Roto-Rooter. The hospice industry, where VITAS is a major provider, is subject to significant regulatory oversight, particularly Medicare Cap limitations, which can directly impact revenue and profitability. The plumbing and drain cleaning industry, served by Roto-Rooter, is influenced by residential and commercial construction, maintenance needs, and economic cycles. The filing indicates that both segments are facing profitability pressures, with VITAS grappling with increased Medicare Cap limitations and Roto-Rooter experiencing declining margins despite slight revenue growth.

Management Changes

Stakeholder Impact

• Shareholders: Will experience a significant negative impact due to the substantial downward revision of full-year earnings guidance and the decline in Q2 EPS. The share repurchase program may offer some support, but the overall financial performance is concerning.
• Employees: The change in leadership at VITAS, with Joel L. Wherley succeeding Nicholas M. Westfall, may lead to some organizational adjustments within the VITAS segment.
• Customers (VITAS): Continued focus on end-of-life care, with efforts to mitigate Medicare Cap risk through expansion activities, suggests ongoing service provision.
• Customers (Roto-Rooter): Services continue, but declining profitability in some residential and commercial service lines could indicate shifts in demand or competitive pressures.

Next Steps

• Chemed will host a conference call and webcast on Wednesday, July 30, 2025, at 10 a.m. ET, to discuss the quarterly results and provide a business update.
• Management intends to update assumptions regarding rates and the overall outlook for 2026 Medicare Cap in Florida in the third quarter earnings release, once detailed rate information becomes available.

Key Dates

Recommendation

The significant downward revision of full-year adjusted diluted EPS guidance by over 10% from previous estimates, coupled with a substantial increase in Medicare Cap billing limitations for the VITAS segment and declining profitability across both VITAS and Roto-Rooter segments, signals deteriorating financial performance. The executive departure at VITAS adds an element of uncertainty. While the company maintains a strong cash position and no debt, the core operational challenges and reduced earnings outlook warrant a 'sell' recommendation for investors seeking to mitigate risk or reallocate capital.

Keywords

Chemed Corporation, VITAS Healthcare, Roto-Rooter, Hospice care, End-of-life care, Plumbing services, Drain cleaning, Q2 2025 earnings, Financial results, EPS guidance, Medicare Cap, Executive departure, Healthcare industry, Home services